drugset / Trial / NCT03597529

CHOCOlate MeLatonin for AdolescenT MigrainE

NCT03597529

Phase 2 Completed 84 enrolled Amy Gelfand
RandomizedParallel-groupOpen-labelTreatment

Summary

Existing treatments for acute migraine are not effective for all children and adolescents, and can cause side effects. Investigator propose a dose-finding study of melatonin for acute migraine treatment in children and adolescents to determine the best dose to bring forward in a future fully-powered efficacy trial.

Timeline

Start
2017-09-25
Primary completion
2019-12-01
Completion
2019-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 1 mg
Subject Melatonin Small molecule 2 mg
Subject Melatonin Small molecule 4 mg
Subject Melatonin Small molecule 8 mg

Indications